Title : Synthesis of some new N-(alkyl\/aralkyl)-N-(2,3-dihydro-1,4-benzodioxan-6-yl)-4-chlorobenzenesulfonamide s as possible therapeutic agents for Alzheimer's disease and Type-2 Diabetes - Abbasi_2019_Pak.J.Pharm.Sci_32_61 |
Author(s) : Abbasi MA , Rehman A , Siddiqui SZ , Hadi N , Mumtaz A , Shah SAA , Ashraf M , Abbasi GH |
Ref : Pak J Pharm Sci , 32 :61 , 2019 |
Abstract :
In the current research work, a series of new N-(alkyl/aralkyl)-N-(2,3-dihydro-1,4-benzodioxan-6-yl)-4-chlorobenzenesulfonamide s has been synthesized by reacting 1,4-benzozzdioxan-6-amine (1) with 4-chlorobenzenesulfonyl chloride (2) to yield N-(2,3-dihydro-1,4-benzodioxan-6-yl)-4-chlorobenzenesulfonamide (3) which was further reacted with different alkyl/aralkyl halides (4a-n) to afford the target compounds (5a-n). Structures of the synthesized compounds were confirmed by IR, 1H-NMR, EI-MS spectral techniques and CHN analysis data. The results of enzyme inhibition showed that the molecules, N-2-phenethyl-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-chlorobenzenesulfonamide (5j) and N-(1-butyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-chlorobenzenesulfonamide (5d), exhibited moderate inhibitory potential against acetylcholinesterase with IC50 values 26.25+/-0.11 muM and 58.13+/-0.15 muM respectively, whereas, compounds N-benzyl-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-chlorobenzenesulfonamide (5i) and N-(pentane-2-yl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-chlorobenzenesulfonamide (5f) showed moderate inhibition against alpha-glucosidase enzyme as evident from IC50 values 74.52+/-0.07 and 83.52+/-0.08 muM respectively, relative to standards Eserine having IC50 value of 0.04+/-0.0001 muM for cholinesterases and Acarbose having IC50 value 38.25+/-0.12 muM for alpha-glucosidase, respectively. |
PubMedSearch : Abbasi_2019_Pak.J.Pharm.Sci_32_61 |
PubMedID: 30772791 |
Abbasi MA, Rehman A, Siddiqui SZ, Hadi N, Mumtaz A, Shah SAA, Ashraf M, Abbasi GH (2019)
Synthesis of some new N-(alkyl\/aralkyl)-N-(2,3-dihydro-1,4-benzodioxan-6-yl)-4-chlorobenzenesulfonamide s as possible therapeutic agents for Alzheimer's disease and Type-2 Diabetes
Pak J Pharm Sci
32 :61
Abbasi MA, Rehman A, Siddiqui SZ, Hadi N, Mumtaz A, Shah SAA, Ashraf M, Abbasi GH (2019)
Pak J Pharm Sci
32 :61